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Abstract: The ectonucleotidases CD39 and CD73 degrade ATP to adenosine which inhibits immune responses via 
the A2A adenosine receptor (ADORA2A) on T and NK cells. The current study investigates the potential therapeutic 
use of the specific anti CD39- and anti CD73-antibodies A1 (CD39) and 7G2 (CD73) as these two ectonucleotidases 
are overexpressed in ovarian cancer (OvCA). As expected, NK cell cytotoxicity against the human ovarian cancer cell 
lines OAW-42 or SK-OV-3 was significantly increased in the presence of A1 or 7G2 antibody. While this might partly 
be due to antibody-dependent cell-mediated cytotoxicity, a luciferase-dependent assay for quantifying biologically 
active adenosine further showed that A1 and 7G2 can inhibit CD39 and CD73-dependent adenosine-generation. In 
turn, the reduction in adenosine levels achieved by addition of A1 and 7G2 to OAW-42 or SK-OV-3 cells was found 
to de-inhibit the proliferation of CD4+ T cells in coculture with OvCA cells. Likewise, blocking of CD39 and CD73 on 
OvCA cells via A1 and 7G2 led to an increased cytotoxicity of alloreactive primed T cells. Thus, antibodies like A1 and 
7G2 could improve targeted therapy in ovarian cancer not only by specifically labeling overexpressed antigens but 
also by blocking adenosine-dependent immune evasion in this immunogenic malignancy.
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Introduction
In spite of all efforts to develop new therapeutic 
strategies for ovarian cancer (OvCA), its bleak 
prognosis has remained largely unchanged 
since the introduction of the platinum-based 
chemotherapies about thirty years ago [1]. For 
the so-called “developed countries” where 
treatment options should be optimal, epidemio-
logical data still report an annual number of 
more than 64.500 deaths from ovarian cancer 
which indicates that a majority of the annually 
100.300 patients diagnosed with the disease 
will ultimately succumb to it [2]. Therefore, new 
approaches for improving the medical manage-
ment of OvCA-patients urgently need to be 
identified. 
There is growing evidence that interactions with 
the immune system are clinically most relevant 
for this type of cancer [3]. For example, 
increased recruitment of regulatory T cells (Treg) 
by OvCAs correlates with a significantly 
increased mortality, presumably by suppress-
ing the host’s spontaneous immune responses 
to tumor antigens [4, 5]. One key mechanism 
for immunomodulation by Treg seems to be the 
generation of extracellular adenosine. 
CD4+CD25+FoxP3+ Treg were shown to use 
CD39/ENTPD1 and CD73/ecto-5’-nucleotidase 
to hydrolyze adenosine tri- and diphosphate 
(ATP/ADP) to adenosine which in turn exerts 
immunosuppression on various immune cell 
populations [6-9].
Investigating CD39- and CD73-positive cells in 
ovarian cancer we found that OvCA cells them-
selves express both ectonucleotidases and pro-
duce about 30-60 times more biologically 
active adenosine than Treg. Furthermore, we 
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could show that CD39- and CD73-mediated 
adenosine-production by OvCA cells suppress-
es NK and T cell cytotoxicity as well as CD4+ T 
cell proliferation. Also immunohistochemical ex 
situ stainings of OvCA tissue showed strongly 
increased ectonucleotidase expression com-
pared to benign ovarian tissue (all: [10]).
This prompted us to investigate if CD39 and 
CD73 could be new targets for immunomodula-
tory therapies in ovarian cancer. Therefore, we 
tested if specific antibodies against CD39 and 
CD73, A1 and 7G2, could improve immune 
responses against ovarian cancer cells. A spe-
cial focus was placed on the ability of the anti-
bodies to inhibit adenosine generation by both 
ectonucleotidases.
Materials and methods
Cell culture
The human ovarian cancer cell lines SK-OV-3 
(American Type Culture Collection (ATCC) HTB-
77) and OAW-42 (European Cell Culture 
Collection 85073102) were cultured in RPMI 
1640 medium with 10% FCS (Biochrom, Berlin, 
Germany), 0.02% sodium pyruvate, penicillin 
(100 IU/ml) and streptomycin (100 µg/ml) (all 
from PAA, Pasching, Austria). In order to detach 
the cells for further experimental use, Accutase 
(PAA) was used. Cell line identity was confirmed 
using the single tandem repeat fingerprint sys-
tem as performed by the Deutsche Sammlung 
für Mikroorganismen und Zellkulturen (Braun- 
schweig, Germany).
Flow cytometric analysis of specific CD39 and 
CD73 surface expression on OvCa cells using 
antibodies A1 and 7G2
Detached Ovarian cancer cells (106/sample) 
were blocked and stained with mouse anti-
human CD39 (clone A1, #MCA1268XZ, AbD 
serotec, Oxford, UK) or mouse anti-human 
CD73-antibody (clone 7G2, #ab54217, Abcam, 
Cambridge, UK). FITC-conjugated goat anti 
mouse antibodies (22549913, Immunotools, 
Friesoythe, Germany) were used for visualiza-
tion. 50,000 cells were assessed for expres-
sion of CD39 or CD73 using a FACScan flow 
cytometer (BD Biosciences, San Jose, USA). 
Specific fluorescence indices (SFI) were obtain- 
ed by dividing mean fluorescence recorded with 
the specific antibodies by the fluorescence 
intensity obtained with the corresponding iso-
type controls (n=3).
NK cell preparation and cytotoxicity assays
Polyclonal NK cell populations were obtained 
by co-culturing peripheral blood leucocytes 
(PBL) from healthy volunteers with irradiated 
(30 Gy) RPMI 8866 feeder cells [11]. PKH26 
(Sigma-Aldrich St. Louis, MO, USA) was used to 
label the NK cells according to the manufac-
turer’s instructions. Their lytic activity against 
5-(and-6)-carboxyfluorescein diacetate succin-
imidyl ester (CFDA-SE, LifeTechnologies, 
Darmstadt, Germany) target cells (50.000 tar-
get cells/well) [12] was determined in modified 
4h FATAL assays. For triggering antibody-
dependent cellular cytotoxicity (ADCC), anti-
human CD39 (A1, AbD serotec) or anti-human 
CD73-antibody (7G2, Abcam) or, respectively, 
an isotype control antibody were added at 
1 µg/ml. For further control purposes, the A2A 
adenosine receptor inhibitor SCH58261 
(100 nM, Tocris, Bristol, UK) or a suitable sol-
vent control was applied. Using a FACScan flow 
cytometer, tumor cell lysis was measured at dif-
ferent effector/target cell ratios. CFDA-SEdim 
cells within the PKH-26 negative cell population 
were counted as lysed cells. Spontaneous leak-
age of CFDA-SE was controlled by culture with 
solvent only.
Adenosine production via CD39 and CD73
Biologically active adenosine within the cellular 
microenvironment was determined as descri- 
bed in [13] and [10]. 104 freshly detached OAW-
42 cells were co-incubated with equal numbers 
of RIP1-CRE.luc- and pRL-CMV-transfected 
HEK-293 ADORA2A+/- cells in 96-well plates. 
During this incubation, A1 (anti-human CD39) 
or 7G2 (anti-human CD73) were added at 
10 µg/ml to block CD39 or CD73 function. After 
4h, the cells were lysed in passive lysis buffer 
(Promega). Using a non-commercial dual lucif-
erase assay [14], the biophotonic signals were 
quantified in an Orion II Microplate Luminometer 
(Berthold Detection Systems, Pforzheim, Ger- 
many). All values were measured in triplicates.
Proliferation of CD4+ T cells in co-culture with 
OvCA cells
The “CD4+ T cell isolation kit II” was used to iso-
late CD4+ T cells from PBL; CD4+CD25+ and 
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CD4+CD25- T cells were obtained using the 
“CD4+CD25+ regulatory T cell isolation kit” 
(both from Miltenyi Biotec, Bergisch Gladbach, 
Germany). Directly after isolation the T cells 
were labeled with 2.5 µM CFDA-SE (Invitrogen). 
To induce proliferation, anti-human CD3 (clone 
UCHT-1, Immunotools) at 1 µg/ml was immobi-
lized on 96 well Maxisorp-plates (Nunc, 
Roskilde, Denmark) by overnight-incubation in 
PBS. In each pre-coated well, 2×106 T cells 
were then co-incubated with anti-human CD28 
(clone 15E8, ImmunoTools, at 1 µg/ml) and 
with 5×105 SK-OV-3 or OAW-42 cells. CD39 and 
CD73 were blocked by addition of anti-human 
CD39 (A1, AbD serotec) or anti-human CD73 
antibody (7G2, Abcam). Specificity was ensured 
by use of an isotype control (MG1-45, 
BioLegend, San Diego, USA) or the ADORA2A 
antagonist SCH58261 (100 nM, Tocris). All anti-
bodies were used at 10 µg/ml. Where indicat-
ed, adenosine (Sigma-Aldrich, St. Louis, USA) 
was added at 100 µM. A FACScan flow cytom-
eter (BD Biosciences) was used to measure 
proliferation on day 7 [15]. Calculation of prolif-
eration rates in FACS analyses was performed 
as outlined in [10]: the absolute number of 
counts in each peak-region of the correspond-
ing CFDA-SE histogram was divided by 2n (n 
standing for the number of the peak, being 
counted from right to left and beginning with 0) 
to calculate the number of cells “x” which origi-
nally divided into the cells of the peak. 
2x
0
1
i
i
n
)
=
-
^ h/  is equal to the total number of cell 
division per peak n.
T cell response to recall antigens
Co-culturing PBMC with IL-2 (30 U/ml) and irra-
diated (10 Gy) ovarian cancer cell lines SK-OV-3 
or OAW-42 at a ratio of 15:1 provided antigen-
specific, alloreactive CD8+ T cells [12, 16, 17]. 
To specifically block CD39 or CD73 during prim-
ing of the PBMC, anti-human CD39 (A1), anti-
human CD73 (7G2) or an isotype control were 
added at 1 µg/ml. SCH58261 (100 nM) was 
used to inhibit ADORA2A. After an incubation 
period of 14 days, the PBMC were labeled with 
PKH-26. The lytic activity against fresh CFDA-
SE-labeled SK-OV-3 or OAW-42 cells at different 
effector to target cell ratios was determined 
after 4h, using modified FATAL assays as 
described above.
Statistics
Flow cytometric data was evaluated using 
Summit v4.1 and v4.3 (DakoCytomation, Fort 
Collins, USA). Further calculations including 
statistical computations were done using 
Microsoft Office Excel 2007 and 2013 
(Microsoft, Redmond, USA). Significance levels 
were determined by Student’s t-test. p-values < 
0.05 were considered as significant (*), p < 
0.01 as highly significant (**). In flow cytomet-
ric assays, two samples were considered to be 
significantly different (*) when they were sepa-
rated by at least twice the sum of the standard 
deviations for the respective regions. A differ-
ence exceeding four times the sum of the 
respective standard deviations was considered 
as highly significant (**).
Results
Specific labeling of SK-OV-3 and OAW-42 by 
the anti-human CD39- and anti-human CD73-
antibodies A1 and 7G2
To confirm the binding of A1 (anti CD39) and 
7G2 (anti CD73) to the human ovarian cancer 
cell lines SK-OV-3 and OAW-42, the cells were 
incubated with either antibody or an isotype 
control. Binding was visualized with FITC-
conjugated secondary antibodies and analysed 
by flow cytometry. For A1, the Specific 
Fluorescence Indices (SFIs) of 3.3 (SK-OV-3) 
resp. 20.0 (OAW-42) were determined (Figure 
1, upper panels). The CD73-antibody 7G2 yield-
ed SFI values of 48.1 for SK-OV-3 and 105.6 for 
OAW-42 (Figure 1, lower panels).
Lytic activity of polyclonal NK cells against SK-
OV-3 or OAW-42 is increased by antibodies A1 
and 7G2
To assess the effect of the antibodies A1 and 
7G2 on NK cell-mediated killing of OvCA tar-
gets, polyclonal NK cell cultures were obtained 
from healthy volunteers [11] and stained with 
PKH-26. Freshly detached SK-OV-3 and OAW-
42 cells were stained with CFDA-SE. The PKH-
26-labeled polyclonal NK cells were co-incubat-
ed with CFDA-SE-loaded OvCA cells at different 
effector to target ratios in modified 4h FATAL 
assays [12]. During this incubation A1, 7G2 or 
an isotype control antibody were present. Flow 
cytometry was used to determine the percent-
age of PKH-26- CFDA-SEdim OvCa cells after 4h. 
Anti-CD39 and anti-CD73 antibodies for therapy of ovarian cancer
132 Am J Transl Res 2014;6(2):129-139
Applying A1 and 7G2 caused significantly 
improved lytic activity of polyclonal NK cells 
against SK-OV-3 (Figure 2, left) and OAW-42 
(Figure 2, right) cells as compared to isotype 
controls. Both antibody-dependent cellular 
cytotoxicity (ADCC) mediated by NK cells recog-
nizing IgG-decorated OvCA targets and the 
relief of adenosine-dependent NK cell inhibi-
tion may contribute to this effect. In line with 
our previous findings [10], we also observed a 
significant increase in target cell lysis when the 
specific Adenosine Receptor 2a (ADORA2A)-
Inhibitor SCH58261 was applied (data not 
shown) which suggests that the effect was not 
only due to ADCC. Due to the lack of suitable 
reagents, antibody-mediated blockade of ADO- 
RA2A could not be tested.
Antibodies A1 and 7G2 specifically block en-
zymatic adenosine generation by CD39 and 
CD73 expressed on SK-OV-3 and OAW-42 cells
As blocking of the adenosine signal by 
SCH58261 led to a similar increase in lytic 
activity of NK cells against OvCA cells as the 
application of the anti CD39-/anti CD73-
antibodies, we wondered if A1 and 7G2 could 
interfere with adenosine generation by ectonu-
cleotidases. Therefore, we used the luciferase-
based reporter assay for the measurement of 
biologically active adenosine described in [13]. 
In this assay, ADORA2A-overexpressing HEK- 
293-“sensor cells” containing a cAMP reporter 
plasmid are placed in the cellular microenviron-
ment of potentially adenosine-producing cells. 
To normalize for transfection efficiency, the fire-
fly luciferase-based cAMP reporter plasmid is 
co-transfected with a constitutively expressed 
renilla reniformis luciferase (pRL-CMV). These 
sensor cells then express a firefly luciferase in 
response to adenosine receptor stimulation 
which can be quantified and normalized by con-
ventional dual luciferase assays. When OAW-42 
were co-incubated with these sensor cells, 
addition of A1 anti-CD39 antibody resulted in a 
> 60%-decrease of the measured adenosine 
concentration compared to an unspecific iso-
type control (Figure 3). Application of 7G2 anti-
CD73 mAb in the same setting reduced ade-
nosine levels by 62% (Figure 3), the combina-
tion of A1 and 7G2 by 64% (Figure 3) confirming 
that these anti CD39 and anti CD73 antibodies 
inhibit enzymatic adenosine generation by 
ectonucleotidases.
Blockade of CD39 and CD73 via A1 and 7G2 
antibodies increases proliferation of CD4+ T 
cells in co-culture with SK-OV-3 and OAW-42 
ovarian cancer cells
To investigate if the anti-CD39 and anti-CD73 
antibodies A1 and 7G2 de-inhibit adenosine-
Figure 1. Specific binding of antibodies A1 and 7G2 to SK-OV-3 and OAW-42 cells. Freshly detached ovarian cancer 
cell lines SK-OV-3 (left) or OAW-42 (right) were stained either with the mouse anti human CD39-antibody A1 or 
the mouse anti human CD73-antibody 7G2 (dark), both used at 10 µg/ml. After application of a secondary FITC-
conjugated anti mouse-antibody, the specific fluorescence indices (“SFI”, indexed in the upper right corner of the 
histograms) for either CD39 or CD73 were determined in comparison to isotype-matched control antibodies of ir-
relevant specificity (light).
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mediated suppression of CD4+ T cell prolifera-
tion, activated CFDA-SE-labeled CD4+ T cells 
were incubated with irradiated SK-OV-3 or 
OAW-42 OvCA cells and both antibodies. An 
example for the effect of A1 on co-cultures of 
CFDA-SE-labeled CD4+ T and SK-OV-3 cells is 
shown in Figure 4A. Compared to an isotype 
antibody of irrelevant specificity, CD4+ T cell 
proliferation measured by flow cytometry 
almost doubled (Figure 4A). Likewise, the com-
bination of A1 and 7G2 antibodies with either 
OAW-42 or SK-OV-3 cells also yielded highly sig-
nificant increases in CD4+ T cell proliferation, 
again compared to isotype control antibodies 
directed against an irrelevant control antigen 
(Figure 4B). When instead of A1 or 7G2 anti-
bodies the specific ADORA2A-inhibitor SCH- 
58261 was present in the OvCA/T cell co-cul-
tures, comparable increases in CD4+ T cell pro-
liferation were achieved (Figure 4B). Additio- 
nally, we wanted to confirm that the observed 
de-inhibition of CD4+ T cell proliferation in the 
presence of A1 and 7G2 antibodies could be 
reverted by exogenous addition of adenosine. 
Therefore, the aforementioned co-culture with 
OAW-42 and CD4+ T cells was repeated either 
in the absence or presence of 100 µM exoge-
nously added adenosine. As shown in Figure 
4C, the pro-proliferative effect of blocking 
CD39 (left panel) and CD73 (middle panel) with 
A1 and 7G2 in these co-culture settings could 
be more than abolished by exogenous adenos-
ine. SCH58261, in contrast, still increased the 
T cell proliferation when applied in presence of 
Figure 2. Anti-CD39 and anti-CD73 antibodies A1 and 7G2 enhance cytolytic activity of polyclonal NK cells against 
SK-OV-3 and OAW-42. PKH26 stained polyclonal NK cells (pNK) were co-incubated for 4h with CFDA-SE labeled 
SK-OV-3 (left) or OAW-42 (right) OvCA cells at effector to target cell (E:T) ratios from 40:1 to 5:1 in the presence or 
absence of the antibodies A1 (αCD39, grey, (A)), 7G2 (αCD73, grey, (B)) or an isotype control of irrelevant specificity 
(shaded). As dying OvCA cells release CFDA-SE, modified FATAL-assays were used to determine the percentage of 
lysed cells (“Lysis [%]”) [10] (n=3).
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exogenous adenosine confirming the rescue 
achieved via blockade of ADORA2A (Figure 4C, 
right panel).
T cell responses to recall antigens from SK-
OV-3 or OAW-42 cells are increased when an-
tibodies A1 or 7G2 block the function of CD39 
or, respectively, CD73
Adenosine generated by OvCA cells via CD39 
and CD73 was already shown to interfere with 
the priming of T cell responses against recall 
antigens [10]. To investigate whether blockade 
of CD39 and CD73 by antibodies could relieve 
this suppression, PBMC were isolated from 
healthy volunteers and co-cultured with irradi-
ated human ovarian cancer cell lines SK-OV-3 
and OAW-42 [16, 17] in the absence or pres-
ence of A1 or 7G2 antibody. As additional con-
trol, ADORA2A signaling was blocked with 
SCH58261. In line with our previous findings, 
inhibition of adenosine generation or signaling 
during the 14 days of priming resulted in a sig-
nificantly increased cytotoxic activity of primed 
PBMC against fresh SK-OV-3 OvCA targets 
(Figure 5).
Discussion
Epidemiological data on the impact of CD39 
and CD73 expression on the prognosis of can-
cer patients are discordant which suggests that 
the effect may depend on the respective malig-
nancy [18-21]. Human ovarian cancer cells, 
however, are known to over-express the two 
ectonucleotidases CD39 and CD73 which con-
vert free ATP into immune-regulatory adenos-
ine (compare Figure 1 and [10]). Knockdown of 
CD73 was already shown to increase the sur-
vival of tumor-bearing mice in the immune-com-
petent ID-8 ovarian carcinoma model, especial-
ly when combined with adoptive immunothera-
py [22]. In vitro, human T and NK cells were 
shown to mount improved responses to ovarian 
cancer targets when either CD39 or CD73 or 
the ADORA2A receptor was blocked by small 
molecule inhibitors [10]. The data summarized 
here suggest that specific antibodies against 
CD39 (here shown for clone A1) or CD73 (clone 
7G2) could be valid alternatives to small mole-
cule inhibitors for the targeting of ectonucleo-
tidases in cancer. Apart from the generally good 
biosafety profile of therapeutic antibodies, this 
would enable further effector mechanisms like 
antibody dependent cellular cytotoxicity (ADCC) 
[23] which likely contributed to the significant 
enhancement of target cell killing observed 
when A1 or 7G2 were applied together with 
polyclonal NK cells (Figure 2). In vivo, this might 
be a very significant benefit as evidenced by 
the pivotal role of ADCC for the treatment of 
HER2-positive breast cancer with Trastuzumab 
[24-26]. Moreover, antibodies against CD73 
were not only shown to activate immune 
responses against breast cancer cells [27]. A 
most recent study in immune deficient mice 
also found that an antibody which induced clus-
tering and internalization of CD73 on the sur-
face of cancer cells could inhibit metastasis 
formation in a breast cancer model, indepen-
dent of any effect on CD73 catalytic activity 
[28]. As this effect involved internalization of 
the antibody, antibody-drug conjugates might 
Figure 3. Antibodies A1 and 7G2 block adenosine 
production by CD39 and CD73 expressed on SK-
OV-3 and OAW-42. OAW-42 cells were coincubated 
with RIP1-CRE-luc+ pRL-CMV+ ADORA2A+ HEK-293 
reporter cells at a ratio of 1:1 (104 cells of each 
type/well) for 4h. Adenosine produced during the 
co-culture induces expression of firefly luciferase in 
the HEK-293 reporter cells. Quantification of biologi-
cally active adenosine is based on a standard curve 
[13]. Samples containing an isotype control anti-
body (“ctrl.”) were compared with samples in which 
A1 (“αCD39”) or 7G2 (“αCD73”) or both antibodies 
(“αCD39 + αCD73”) were present. Adenosine levels 
are depicted relative to the controls (n=3).
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also be attractive therapeutic tools for the 
treatment of CD73 overexpressing cancers. 
Likewise, antibody engineering techniques 
enable additional functionalities to be built in, 
Figure 4. Antibodies A1 and 7G2 de-inhibit CD4+ T cell proliferation in co-culture with OAW-42 and SK-OV-3 OvCA 
cells. CFDA-SE-labeled CD4+ T cells were stimulated with plate-bound anti CD3- and soluble anti CD28-antibodies (1 
µg/ml each) and co-incubated with SK-OV-3 or OAW-42 OvCA cells. Antibodies A1 (“αCD39”) or 7G2 (“αCD73”) or the 
small molecule ADORA2A inhibitor SCH58261 (“SCH58261”) were added to specifically block the function of CD39, 
CD73 or the Adenosine Receptor 2a (ADORA2A). Control settings (“ctrl.”) contained an isotype-matched antibody 
of irrelevant specificity as control (“ctrl.”) for A1 and 7G2, for SCH58261 a control with solvent only was performed. 
Upon each cell division CFDA-SE gets equally distributed between the resulting daughter cells. After seven days, the 
T cell proliferation was determined by flow cytometry. In order to calculate the number of T cell divisions per sample, 
the counts of each peak in its corresponding CFDA-SE-histogram were divided by 2n with n being the number of the 
peak (counting from right to left and beginning with 0) yielding “x” as the number of the cells from which the cells 
found in peak n arose by cell division. 2x
0
1
i
i
n
)
=
-
^ h/  is equal to all cell divisions in the sample [10]. The “proliferation 
relative to control” is calculated by dividing the number of cell divisions of the specific setting with the number of 
the suitable control. A: A representative sample CFDA-SE histogram is shown. In this example, SK-OV-3 cells were 
co-incubated with the CFDA-SE-labeled CD4+ T cells in presence of A1 antibody (“αCD39”, dark) or, respectively, a 
non-binding isotype control (“ctrl”, shaded). B: The proliferation of CD4+ T cells in co-culture with SK-OV-3 (dark) or 
OAW-42 (shaded) cells in the presence or absence of the antibodies A1 (“αCD39”), 7G2 (“αCD73”) or SCH58261 
was quantified relative to isotype/solvent controls. A representative experiment is shown. C: CFDA-SE-labeled CD4+ 
T cells were co-incubated with OAW-42 OvCA cells and antibodies A1 (“αCD39”, left), or 7G2 (“αCD73”, middle), 
or the ADORA2A inhibitor SCH58261 (“SCH58261”, right) or isotype/solvent controls (“isotype”/“ctrl.”) in the pres-
ence or absence of an excess of exogenous adenosine (“adenosine”). n=3 for all experiments.
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e.g. to enhance ADCC or to improve anti-cancer 
specificity via bispecific targeting. Drawbacks 
are, of course, the high cost of biologicals and 
possibly a lesser tissue penetration as com-
Figure 5. Antibodies A1 and 7G2 enhance the cytotoxic response of alloantigen-primed T cells against OAW-42 and 
SK-OV-3 OvCA targets. PBMC from healthy volunteers were co-incubated with SK-OV-3 (left) or OAW-42 cells (right) in 
the presence or absence of antibodies A1 (“αCD39”, shaded, (A)) or 7G2 (“αCD73”, shaded, (B)), or the ADORA2A 
inhibitor SCH58261 (“SCH58261”, shaded, (C)). After 14 days, the PBMC were harvested and their cytotoxicity 
against freshly detached CFDA-SE-labeled OAW-42 or SK-OV-3 cells was assessed via flow cytometry. Lysis rates 
(=CFDA-SEdim cells divided by total cell numbers, “Lysis [%]”) measured for cells primed in the presence of anti-CD39 
or anti-CD73 antibody or SCH58261 (shaded lines) were compared to the lytic activity of cells to which only an ir-
relevant isotype control antibody or, respectively, solvent had been added during the priming phase (dark lines). A 
representative out of 3 experiments is shown. In all assays, several effector to target ratios were used.
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pared to small molecule inhibitors. In addition, 
the antibody clones available for our study may 
not have been the ones that would be optimal 
for further clinical development.
Still, the enhancement in NK cell cytotoxicity 
achieved with antibodies against either CD39 
or CD73 was similar to the effect observed 
upon blockade of adenosine-triggered, immu-
nomodulatory signaling by SCH58261, a highly 
potent ADORA2A inhibitor [29] (Figure 2). 
Considering that ADCC was likely present with 
the antibodies, but not with SCH58261, this 
raises the question if the antibodies could effi-
ciently suppress adenosine generation by OvCA 
cells. In fact, we found adenosine production to 
be significantly (60-70%) reduced by the anti-
bodies (compare Figure 3) though not fully 
abrogated. With regard to the level of ADCC, 
limitations arise from the fact that both anti-
bodies were generated in mice which could 
result in suboptimal recognition of surface-
bound A1 or 7G2 by human effector cells, even 
though recognition as such should still be pos-
sible (e.g. [23]). Apart from increased NK cell 
killing which can be ascribed to both ADCC and 
reduced adenosine levels, the antibodies A1 
and 7G2 could also de-inhibit the proliferation 
of CD4+ T cells in co-culture with OvCA cells, an 
effect that could be reverted by exogenous 
addition of adenosine (Figure 4). Finally, the 
cytotoxic capacity of alloreactive, OvCA-antigen-
primed CD8+ T cells was significantly enhanced 
when the antibodies were present during the 
priming phase (Figure 5). This is fully compati-
ble with studies performed by Stagg et al. and 
Jin et al. who have shown impressive effects 
upon inhibition of CD73 in animal models for 
breast and ovarian cancer [22, 27]. Our data 
are also in line with findings from Ohta and col-
leagues who described that mice lacking the 
most potent immunomodulatory adenosine 
receptor, ADORA2A, could generate improved 
antitumoral CD8+ T cell responses leading to 
reduced growth of experimental tumors [8]. 
Even though the targets are not strictly tumor-
specific, studies which explored in vivo target-
ing of ectonucleotidases (or ADORA2A) for can-
cer treatment did not report any critical side 
effects. Moreover, the manifold immune regula-
tory effects of adenosine (e.g. [30]) were 
described to be involved in the suppressive 
action of regulatory T cells expressing CD39 
and CD73 [6, 7]. Considering that Treg are 
recruited by human ovarian cancers and that 
infiltration of ovarian tumor tissue by Treg is 
strongly associated with poor prognosis [4], an 
additional targeting of Treg via antibodies direct-
ed at CD39 and CD73 could have further ben-
eficial effects. In fact, CD39-based strategies 
aiming at the selective functional inhibition of 
Treg without depletion are already being devel-
oped [31]. Moreover, the increasing repertoire 
of targeted anti-cancer therapies is also begin-
ning to offer manifold possibilities for intelligent 
combinations. In this context, reports that 
CD39 and CD73 promote the survival of cells in 
hypoxic areas are of interest: necrotic cells 
tend to release high levels of ATP which is not 
only an immunological danger signal, but which 
can also have direct cytotoxic effects on tumor 
cells [32, 33]. Prevention of ATP hydrolysis via 
targeting of CD39 and CD73 could thus increase 
hypoxic stress on cancer cells. Ovarian cancer 
cells are known to counteract hypoxia by secret-
ing the pro-angiogenic cytokine vascular endo-
thelial growth factor (VEGF) [34]. The four 
phase III trials ICON7 [35], GOG-0128 [36], 
OCEANS [37] and AURELIA [38] have recently 
shown that the blockade of VEGF with the 
humanized antibody Bevacizumab is beneficial 
both for the adjuvant as well as for the palliative 
treatment of ovarian cancer. Accordingly, a 
combination of Bevacizumab with antibodies 
directed at CD39 or CD73 could yield synergis-
tic effects by decreasing tumor vascularization 
and by reducing the ability of cancer cells to 
survive within hypoxic areas.
Taken together, the results obtained in our 
human in vitro model system support the 
murine studies which have shown that CD39 
and CD73 are expressed on OvCA cells and that 
their inhibition can relieve adenosine-depen-
dent immunosuppression. Using antibodies 
instead of small molecule inhibitors offers addi-
tional effects like ADCC or antibody-induced 
internalization of the receptor. Antibody-based 
therapeutics like bispecific constructs could be 
generated to further enhance tumor specificity 
or actively induce the recruitment of immune 
effector cells. Consequently, antibodies to 
CD39 and CD73 should be further investigated 
in vivo, as they may become valuable tools for 
the treatment of otherwise incurable cases of 
ovarian cancer.
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